Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis

Journal of the American Academy of Dermatology

Volumn 67, Issue 4, 2012, Pages 636-641

  Keaney, Terrence Colin ^a   Bhutani, Tina ^b   Sivanesan, Priya ^c   Bandow, Grace D ^c   Weinstein, Sari Beth ^d   Cheung, Lawrence C C ^d   Malick, Farah ^e   Koo, John ^f  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

atopic dermatitis; calcineurin inhibitor; oral tacrolimus; sequential therapy; topical tacrolimus

Indexed keywords

CREATININE; PLACEBO; TACROLIMUS; URIC ACID;

ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TOPICAL TREATMENT; URIC ACID BLOOD LEVEL; VOMITING;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; CALCINEURIN; DERMATITIS, ATOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866377557     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.10.033     Document Type: Article

References (19)

1. F. Schultz-Larsen, and J.M. Hanifin Epidemiology of atopic dermatitis Immunol Allergy Clin North Am 22 2002 1 24
2. S.M. Langan What is meant by a "flare" in atopic dermatitis? Arch Dermatol 142 2006 1190 1196
3. J. Koo, G. Kochavi, and J.C. Kwan Introduction J. Koo, G. Bandow, J. Hong, T. Keaney, B. Koo, J. Kwan, M.-L. Pang, Contemporary diagnosis and management of psoriasis 1st ed. 2004 Handbooks in Health Care Co Newtown (PA) 5
4. C. Ellis, T. Luger, D. Abeck, R. Allen, R.A.C. Graham-Brown, and Y. De Prost International consensus conference on atopic dermatitis II (ICCAD II): clinical update and current treatment strategies Br J Dermatol 148 2003 3 10
5. J. Schmitt, K. Schakel, N. Schmitt, and M. Meurer Systemic treatment of severe atopic dermatitis Acta Derm Venereol 87 2007 100 111
6. B. Schroer, and R. Lockey Oral tacrolimus for severe recalcitrant atopic eczema J Allergy Clin Immunol 111 2003 1409
7. J.Y. Koo, A.B. Fleischer, W. Abramovits, D.M. Pariser, C.O. McCall, and T.D. Horn Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients J Am Acad Dermatol 53 Suppl 2005 S195 S205
8. J.M. Hanifin, A.S. Paller, L. Eichenfield, R.A. Clark, N. Korman, and G. Weinstein Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis J Am Acad Dermatol 53 Suppl 2005 S186 S194
9. J. Koo Systemic sequential therapy of psoriasis: a new paradigm for improved results J Am Acad Dermatol 41 Suppl 1999 S25 S28
10. A.C. Webster, R.C. Woodroffe, R.S. Taylor, J.R. Chapman, and J.C. Craig Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data BMJ 331 2005 810
11. Immunosuppression: 2004 annual report of the US organ procurement and transplantation network and the scientific registry of transplant recipients: transplant data 1994-2003 2004 HHS/HRSA/OSP/DOT and UNOS Ann Arbor (MI)
12. I.H. Klein, A. Abrahams, T. Van Ede, R.J. Hene, H.A. Koomans, and G. Ligtenberg Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects Transplantation 73 2002 732 736
13. S. Masuda, and K. Inui An update review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients Pharmacol Ther 112 2006 184 198
14. European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study Arch Dermatol 132 1996 419 423
15. B.A. Teicher Malignant cells, directors of the malignant process: role of transforming growth factor-beta Cancer Metastasis Rev 20 2001 133
16. A. Khanna, V. Cairns, and J.D. Hosenpud Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells Transplantation 67 1999 614 619
17. M. Maluccio, V. Sharma, M. Lagman, S. Vyas, H. Yang, and B. Li Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression Transplantation 76 2003 597 602
18. S. Euvrard, C. Ulrich, and N. Lefrancois Immunosuppressants and skin cancer in transplant patients: focus on rapamycin Dermatol Surg 30 2004 628 633
19. D.J. Hijnen, O. Ten Berge, L. Timmer-de Mik, C.A. Bruijnzeel-Koomen, and M.S. de Bruin-Weller Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis J Eur Acad Dermatol Venereol 21 2007 85 89